Which immune cells contribute towards immune-induced neurodegeneration and how could this knowledge enable conditions such Alzheimer’s and multiple sclerosis to be treated?
List view / Grid view
Parkinson's disease (PD)
Filter the results
The Genome Aggregation Database (gnomAD) Consortium has released seven papers leveraging its database to study genetic variants and their potential for guiding discovery of safer drugs.
Novel promoters based on those in the herpes viruses, enabled delivery of larger genes and increased the period they were active in the nervous system.
Scientists used optical photothermal spectroscopy (O-PTIR) to image murine neurons affected by early stage Alzheimer’s disease, providing insight into the progression of the disease.
Scientists have identified two master controller regions that are essential for alpha-synuclein aggregation and could be targeted by future therapies.
Scientists in the US have applied a novel technique to finally unravel a particular kinase enzyme that is associated with familial Parkinson’s disease; providing a clearer potential therapeutic target.
Research into age-related chronic inflammatory disorders has identified an ‘off switch’ on the NLRP3 inflammasome that could be targeted in new therapies.
Research identified a small molecule that targets the mRNA of α-synuclein and prevents the formation of the protein, an approach which could provide novel neurodegeneration therapies.
Research has identified that regions of the brain can regenerate via neural stem cells and the process of neurogenesis which could provide a new avenue for regenerative therapeutics.
Researchers have discovered an enzyme that blocks a genetic pathway that causes Parkinson’s, which could be used as a treatment in the future.
This article highlights five of the latest findings that could be used in the development or design of new therapies to treat Parkinson’s disease.